Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Börse Stuttgart
Equities
2TZ
CNE100000924
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.196 EUR | -2.27% | -6.28% | +21.02% |
May. 15 | Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Directorate and Committee Changes | CI |
Apr. 30 | Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3% | MT |
Strengths
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+21.02% | 3.17B | - | ||
+34.14% | 5.87B | B- | ||
-30.04% | 3.71B | C+ | ||
-22.68% | 2.71B | B- | ||
-8.17% | 2.36B | - | D+ | |
+42.02% | 1.89B | - | ||
+45.22% | 1.5B | - | ||
-12.58% | 1.44B | - | - | |
+40.95% | 1.35B | - | ||
-27.42% | 1.32B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 600329 Stock
- 2TZ Stock
- Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited